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In a recent paper, Loriot et al. [1] explored the issue of whether carboplatin plus etoposide regimen is more 
active in castration-resistant prostate cancer patients with neuroendocrine differentiation as opposed to 
those without. In a patient population resistant to docetaxel therapy, they observed a prostate-specific 
antigen (PSA) response rate in 18% and 31% of patients with normal and elevated serum chromogranin A 
(CgA), respectively. These results indicate a possible role of neuroendocrine differentiation in predicting 
efficacy of cisplatin-based regimen.  
How to explain these data? Platinum-containing regimens are notoriously efficacious in the treatment of 
pure poorly differentiated neuroendocrine prostate carcinoma that is an extremely rare phenotype [2]. In 
most cases of prostate cancer with neuroendocrine differentiation, the neuroendocrine cell population 
coexists with a predominant exocrine phenotype. Noteworthy, these neuroendocrine cells are apparently 
terminal cells, since they do not proliferate. Conceivably, they could negatively influence the prognosis by 
stimulating the exocrine component of the tumor to proliferate via paracrine mechanisms [3]. On these 
bases, there is no rationale supporting a greater sensitivity of prostate cancer with neuroendocrine 
differentiation to cisplatin-containing regimens. 
We report on a case that was recently addressed to our institution. A 69-year-old patient had a castration-
resistant prostate carcinoma with multiple bilateral lung metastases and metastatic bone lesions. Radical 
prostatectomy was carried out in 2002 and an adenocarcinoma, Gleason score 7, stage pT3b pN0 was 
found. CgA immunoreactivity was detected in 1% of tumor cells. Preoperative serum PSA was 7 ng/ml. 
Two years later, he had been addressed to androgen deprivation therapy (ADT) due to bone progression 
and in March 2006, docetaxel therapy was introduced due to lung metastases development. After three 
chemotherapy cycles, however, a further progression of lung lesions was observed. Serum PSA and plasma 
CgA were 20.4 ng/ml and 62 U/l (normal range <20 U/l), respectively. A fine-needle aspiration biopsy on a 
pulmonary lesion revealed a poorly differentiated neuroendocrine carcinoma, negative for PSA and thyroid 
transcription factor-1 and CgA positive.  
The patient was then treated with eight cycles of carboplatin (area under the curve 6) obtaining a partial 
response of lung lesions (70% decrease on average size) lasting 10 months. When the treatment was 
stopped, the computerized tomography scan documented the persistence of a partial response. Serum PSA 
was 5.65 ng/ml and plasma CgA 15.4 U/l. The patient eventually died 18 months from carboplatin 
treatment start. 
Neuroendocrine differentiation in prostate cancer is predictive of poor prognosis [3]. It is notoriously 
stimulated by ADT as observed both in tumor xenograft [4] and in humans by evaluating prospectively 
circulating levels of CgA [5]. Our case report indicates that ADT-induced neuroendocrine differentiation 
could lead to poorly differentiated neuroendocrine carcinoma and in that case, a platinum containing 
regimen could be potentially more efficacious than docetaxel. It would be interesting to know how many 
patients in the Loriot et al. series, who responded to cisplatin and etoposide, had poorly differentiated 
neuroendocrine cancer, unfortunately a tumor biopsy before entering the trial was not carried out. 
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